What is electroCore?
electroCore is at the forefront of bioelectronic medicine, developing a non-invasive vagus nerve stimulation therapy platform designed to treat a range of neurological conditions. The company's initial focus areas include the preventive and acute treatment of migraines and episodic cluster headaches, as well as paroxysmal hemicrania and hemicrania continua in adults. By targeting the vagus nerve, electroCore aims to offer a novel therapeutic approach that complements or replaces traditional pharmacological treatments, potentially reducing side effects and improving patient quality of life.
How much funding has electroCore raised?
electroCore has raised a total of $227.4M across 7 funding rounds:
Series A
$50M
Debt
$1.5M
Series B
$70M
Stock Offering
$78M
Share Placement
$25M
Debt
$1M
Private Equity
$1.9M
Series A (2014): $50M with participation from Core Ventures Group, Easton Capital, and Merck Global Health Innovation Fund
Debt (2016): $1.5M, investors not publicly disclosed
Series B (2017): $70M supported by American Investment Holdings LLC, The Vinik Family Foundation, Gakasa, Core Ventures Group, and Merck Global Health Innovation Fund
Stock Issuance/Offering (2018): $78M, investors not publicly disclosed
Share Placement (2020): $25M backed by Lincoln Park Capital Fund , LLC
Debt (2020): $1M with participation from PPP
Private Equity (2025): $1.9M, investors not publicly disclosed
Key Investors in electroCore
Core Ventures Group
Core Ventures Group is an investment firm focused on supporting entrepreneurs building valuable businesses, particularly in seed-stage companies with advanced technologies. They leverage extensive networks to help startups overcome early market challenges.
Merck Global Health Innovation Fund
The Merck Global Health Innovation Fund is part of Merck & Co., Inc., a global healthcare company dedicated to delivering innovative solutions through medicines, vaccines, and animal health products.
Easton Capital
Easton Capital Investment Group manages funds for institutional investors, making investments ranging from $2 million to $7.5 million and utilizing strategic co-investment relationships for larger funding rounds.
What's next for electroCore?
With the recent infusion of capital, electroCore is poised for significant expansion and further development of its therapeutic offerings. The company is likely to invest in scaling its commercial operations, broadening its market reach, and potentially exploring new indications for its bioelectronic medicine platform. This strategic financing will also support ongoing research and development efforts, aiming to solidify electroCore's position as a leader in the rapidly evolving field of neuromodulation and bioelectronic therapies. The company's trajectory suggests a strong focus on clinical validation and market penetration to capitalize on the growing demand for innovative neurological treatments.
See full electroCore company page
